Navigation Links
Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
Date:9/17/2012

LA JOLLA, Calif., Sept. 17, 2012 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic-driven solutions to solve a range of global challenges, today announced they have purchased from Febit Holding GmbH the worldwide rights to three families of patents and patent applications related to key synthetic genomic technologies. All related know-how, equipment and technical support for implementation, were also purchased.

This newly acquired SGI technology includes methods for highly parallelized, low-cost oligonucleotide synthesis and retrieval of sequence-validated DNA.  Together, these technologies have the potential to drastically reduce the cost of DNA synthesis, a technical problem the synthetic biology community has faced since the first synthetic gene was produced forty years ago.

"The intellectual property from Febit will strengthen and accelerate SGI's ongoing development and commercialization of a variety of products including algae-based food and nutritional products, biofuels, biochemicals, synthetic vaccines and clean water," said J. Craig Venter, Ph.D., Founder and CEO, SGI. "The ability to construct accurate and inexpensive DNA, together with our current proprietary DNA assembly and genome transplantation methodologies, enable enhanced capacity to synthesize DNA and reprogram cells at a larger scale than what is currently achievable."

The newly acquired SGI patent families include seven issued United States and European patents covering methods to produce polymers, specifically double stranded, synthetic nucleic acids from a variety of oligonucleotides on a solid support; and methods for retrieving sequence verified synthetic nucleic acids following assembly on solid supports.  These methods can be used to quickly synthesize genetic components in parallel, and then selectively assemble the components having the perfect sequence into double stranded genes and larger DNA constructs with minimal errors.

About Synthetic Genomics Inc.

SGI, a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key research and business programs including: developing algae biofuels in alliance with Exxon Mobil Research and Engineering Company, microbial-enhanced hydrocarbon recovery and conversion through an agreement with BP, new and improved food and nutritional products, and clean water technologies. SGI is also involved in synthetically derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a company co-founded with the J. Craig Venter Institute; and to developing sustainable crops and agricultural products through Agradis Inc., a company co-founded with Plenus S.A. de C.V. For more information go to: www.syntheticgenomics.com.

Media Contact: Heather Kowalski, 858-361-0466, hkowalski@syntheticgenomics.com


'/>"/>
SOURCE Synthetic Genomics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
2. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
3. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
4. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
5. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
6. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Adeona Becomes Synthetic Biologics, Inc.
9. Startling results in synthetic chemistry presented in Nature Chemistry
10. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
11. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... cold-pressed fruit and vegetable drink brand is now available on Amazon.com ... LLC to manufacture and distribute the Vegesentials line of juices throughout North ...
(Date:2/27/2017)... A Europe-wide survey of institutes conducted by the Basel ... research treat them with due care. The survey polled a total ... results indicates that there is a strong commitment among animal researchers ... principles of the 3Rs (Refine, Reduce, Replace)  ... What are the 3Rs? ...
(Date:2/27/2017)... 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: ... February 24, 2017 a total of 10,672,750 common share purchase ... common share. Proceeds from the exercise of these warrants totalled ... ... are grateful for this expression of confidence by our warrant ...
(Date:2/27/2017)... 27, 2017 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the ... U.S. Food and Drug Administration (FDA) has accepted ... 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual tablet, ... moderate-to-severe acute pain in a medically supervised setting. ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):